NCT02319772View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Filovirus InfectionsEbola Virus Infection
Interventions
DRUG

BCX4430

DRUG

Placebo

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

BioCryst Pharmaceuticals

INDUSTRY